Taking NSCLC as an example, the expression of EZH2 shows a negative correlation with MET activation and EGFR-TKI resistance, suggesting that EZH2 may serve as a potential biomarker for EGFR-TKI sensitivity. Here, EZH2 is linked to non-small cell lung carcinoma.